Global Keloid Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Elastic Wraps and Ointment.

By Treatment;

Radiation Therapy, Cry Therapy, Surgical Treatment, Laser Treatment, and Interferon.

By End Use;

Hospitals , Dermatology, Clinics, Ambulatory Surgical Centers (ASCs), and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn146106103 Published Date: April, 2025 Updated Date: May, 2025

Introduction

Global Keloid Treatment Market (USD Million), 2021 - 2031

In the year 2024, the Global Keloid Treatment Market was valued at USD 4,468.43 million. The size of this market is expected to increase to USD 6,162.85 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.7%.


Global Keloid Treatment Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 4.7 %


Study Period2025 - 2031
Base Year2024
CAGR (%)4.7 %
Market Size (2024)USD 4,468.43 Million
Market Size (2031)USD 6,162.85 Million
Market ConcentrationHigh
Report Pages326
4,468.43
2024
6,162.85
2031

Major Players

  • Novartis AG
  • RXi Pharmaceuticals, Inc.
  • Sonoma Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Pacific World Corporation
  • Valeant Pharmaceuticals International, Inc.
  • Revitol Corporation
  • Avita Medical Limited
  • Sensus Healthcare
  • Perrigo Company plc.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Keloid Treatment Market

Fragmented - Highly competitive market without dominant players


The Global Keloid Treatment Market is experiencing steady growth, primarily fueled by the rising number of individuals developing keloid scars due to burns, surgeries, piercings, acne, and other skin traumas. Around 10% of the population, particularly those prone to abnormal wound healing, are at risk of keloid formation. The cosmetic and physical discomfort associated with these scars is increasing the demand for advanced and effective treatment solutions.

Surge in Demand for Minimally Invasive Therapies
Non-invasive and minimally invasive treatment options have become the preferred approach, accounting for over 60% of total procedures in the keloid care market. Therapies such as steroid injections, laser treatment, cryotherapy, and silicone-based applications are widely chosen due to their ease of use, shorter recovery times, and fewer complications. The rising emphasis on aesthetic appearance and patient comfort continues to drive the popularity of these solutions.

Advancements in Treatment Modalities
Continual innovation in keloid therapies is reshaping treatment protocols and outcomes. New drug delivery systems and combination therapies are helping reduce recurrence rates, which remain as high as 50% in conventional treatments. Blending methods—such as laser therapy with corticosteroid injections or radiation post-surgery—are proving more effective, offering patients improved long-term results and higher satisfaction.

Rising Awareness and Improved Access to Care
A growing awareness of treatment availability and the psychological burden of keloids—impacting over 70% of affected individuals’ quality of life—has significantly boosted consultation rates. Patients are increasingly seeking professional care for both physical relief and cosmetic correction. Improved access to dermatological care, supported by expanding healthcare infrastructure, is contributing to higher adoption of these therapies across varied demographics.

Pipeline Developments and Future Outlook
The market’s future is being shaped by promising clinical developments, with nearly 30% of pipeline therapies focused on novel strategies such as gene-targeted treatments and anti-fibrotic agents. These innovations aim to tackle the root causes of keloid formation rather than just addressing symptoms. As clinical trials progress and these new options gain approval, the market is set for sustained and dynamic growth.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Treatment
    3. Market Snapshot, By End Use
    4. Market Snapshot, By Region
  4. Global Keloid Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Incidence

        2. Technological Advancements

        3. Rising Aesthetic Awareness

      2. Restraints
        1. High Treatment Costs

        2. Side Effects and Recurrence

        3. Limited Insurance Coverage

      3. Opportunities
        1. Emerging Markets

        2. Innovative Therapies

        3. Telemedicine Growth

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Keloid Treatment Market, By Product, 2021 - 2031 (USD Million)
      1. Elastic Wraps

      2. Ointment

    2. Global Keloid Treatment Market, By Treatment, 2021 - 2031 (USD Million)
      1. Ligature

      2. Radiation Therapy

      3. Cryo Therapy

      4. Surgical Treatment

      5. Laser Treatment

      6. Interferon

    3. Global Keloid Treatment Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Dermatology
      3. Clinics
      4. Ambulatory Surgical Centers (ASCs)
      5. Others
    4. Global Keloid Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis AG
      2. RXi Pharmaceuticals, Inc
      3. Sonoma Pharmaceuticals, Inc
      4. Bristol-Myers Squibb
      5. Pacific World Corporation
      6. Valeant Pharmaceuticals International, Inc
      7. Revitol Corporation
      8. Avita Medical Limited
      9. Sensus Healthcare

      10. Perrigo Company plc.

  7. Analyst Views
  8. Future Outlook of the Market